Eisai: Innovative facility Design and Expansion
Vikas Namjoshi from Eisai gave a talked to an enthralled room about how Eisai had a well define plan when it came to designing their manufacturing..
Posts in the Biologic Manufacturing category
How to categorise #Antibodies
Antibodies: Do you know the difference between a biosimilar, a biobetter and a next generation antibody? There is much confusion through the..
Comparibility in Biologic Manufacturing
At the Biologic Manufacturing World Asia, Wassim Nashabeh from Genentech Inc was telling the room about how comparibility was revolutionising..
BioPharma Opening Plenary
The 2012 edition of the BioPharma Asia Convention opened with a plenary session with the 4 leaders of from the pharmaceutical world. They discussed..
Pfizer: Forging Strategic Alliances With Partners in India and China
One of the most important themes that emerge is that pharmaceutical firms need to look at forging serious partnerships in the economic powerhouses..
Hepatocyte Growth Factor Genetic Medicine: A Novel Therapy for Lymphedema
Presenting on the above topic is Yamada Ei, President and CEO, AnGes MG, Japan. He will be speaking at 5th Annual BioPharma Asia Convention 2012,..
pSivida: a leading company in ophthalmic drug delivery
Presenting on the above topic is Brian Leedman,Vice President,pSivida, Australia. He will be speaking at 5th Annual BioPharma Asia Convention..
World’s first off-the-shelf allogeneic cord-blood stem cell drug CARTISTEM® – Journey to the market
Speaking on the above topic is Antonio Lee, Associate Director,Medipost, South Korea. He will be speaking at 5th Annual BioPharma Asia Convention..
The Ayoxxa Platform for Protein Multiplexing: A Novel Approach for Quantifying Multiple Proteins in Very Small Sample Volumes
Presenting on the above topic is Andreas Schmidt, CEO, Ayoxxa, Singapore. He will be speaking at 5th Annual BioPharma Asia Convention 2012, held..
#Biotech companies gain healthy profits
Despite a sluggish market, shares in biotechnology companies are increasing in value - but the sector is complex, and it can take time for investors..
